Breast Neoplasms
968
124
187
494
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
149 trials with published results (15%)
Research Maturity
494 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.8%
85 terminated out of 968 trials
85.3%
-1.3% vs benchmark
12%
118 trials in Phase 3/4
30%
149 of 494 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 494 completed trials
Clinical Trials (968)
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Safety and Effectiveness of Robotic-Assisted Remote Surgery for Breast Tumors
Impact of Robotic Versus Endoscopic Surgery on Nipple Nerve Function Following Nipple-Sparing Mastectomy for Breast Cancer
Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer
Effectiveness of CadAI-B Dx for Decision Support in Breast Ultrasound
Dissemination of BREASTChoice AIM1-B
Breast Mammogram and Tissue Study
ICG Lymphography Changes Before and After Radiotherapy in Breast Cancer Patients
Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Supervised Exercise in Women With Breast Cancer
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Effects of Online Yoga on the Quality of Life of Breast Cancer Patients
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)